These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 320935

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [L-asparaginase--first specific cytostatic].
    Marquardt H.
    Arzneimittelforschung; 1968 Nov; 18(11):1380-6. PubMed ID: 4885156
    [No Abstract] [Full Text] [Related]

  • 4. [Asparaginase, leukemia and cancer].
    Levy D, Boiron M.
    Bull Cancer; 1969 Nov; 56(4):365-74. PubMed ID: 4928248
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL.
    Anticancer Res; 2007 Nov; 27(4C):2561-72. PubMed ID: 17695416
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
    Roberts J, Schmid FA, Old LJ, Stockert E.
    Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
    [Abstract] [Full Text] [Related]

  • 8. Toxic and immunodepressive effects of L-asparaginase from E. coli and from Erwinia carotovora following chronic administration in rats.
    Celle G, Dodero M, Cuneo P, Picciotto A, Brambilla G, Cavanna M, Pannaciulli I.
    Arzneimittelforschung; 1977 May; 27(11):2046-50. PubMed ID: 341899
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.
    Uren JR, Ragin RC.
    Cancer Res; 1979 Jun; 39(6 Pt 1):1927-33. PubMed ID: 376113
    [Abstract] [Full Text] [Related]

  • 11. [The antitumor activity of L-asparaginase].
    Adamson RH, Fabro S.
    Acta Vitaminol Enzymol; 1969 Jun; 23(3):111-24. PubMed ID: 4897937
    [No Abstract] [Full Text] [Related]

  • 12. [Biological properties of L-asparaginase preparations from E. coli in cell cultures].
    Kondrat'eva NA, Dobrynin IaV, Merkulov MF.
    Antibiotiki; 1978 Jan; 23(1):43-5. PubMed ID: 341799
    [Abstract] [Full Text] [Related]

  • 13. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 14. The effects of immunization to L-asparaginase on antitumor and enzymatic activity.
    Goldberg AI, Cooney DA, Glynn JP, Homan ER, Gaston MR, Milman HA.
    Cancer Res; 1973 Feb; 33(2):256-61. PubMed ID: 4569788
    [No Abstract] [Full Text] [Related]

  • 15. The effect of asparaginase on some animal-tumors.
    Connors TA, Jones M.
    Recent Results Cancer Res; 1970 Feb; 33():180-7. PubMed ID: 4949161
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
    O'Driscoll KF, Korus RA, Ohnuma T, Walczack IM.
    J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the L-asparaginases from Escherichia coli and Erwinia carotovora as immunosuppressants.
    Ashworth LA, MacLennan AP.
    Cancer Res; 1974 Jun; 34(6):1353-9. PubMed ID: 4596965
    [No Abstract] [Full Text] [Related]

  • 19. Comparative experimental evaluation of immunodepressive and toxic effects of L-asparaginase (NSC-109229) from Escherichia coli and from Erwinia carotovora.
    Cavanna M, Celle G, Dodero M, Picciotto A, Pannacciulli I, Brambilla G.
    Cancer Treat Rep; 1976 Mar; 60(3):255-7. PubMed ID: 769978
    [No Abstract] [Full Text] [Related]

  • 20. Antitumor activity and other biologic properties of L-asparaginase (NSC-109229)-a review.
    Adamson RH, Fabro S.
    Cancer Chemother Rep; 1968 Oct; 52(6):617-26. PubMed ID: 4895425
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.